Shares of Idenix Pharmaceuticals plunged Thursday after federal regulators halted trials of its hepatitis C drug due to the potential for heart damage.   Two weeks, Bristol-Myers shut down a clinical trial of its hepatitis C treatment because a patient suffered heart failure during a clinical trial.   The Food and Drug Administration has […]
This content is only available to members of the CSBJ. To gain access, you'll need to sign in or purchase Digital, Digital Partnership, Silver Membership, Print & Digital, Print, Digital and The Transcript, Corporate Membership or Digital Monthly If you're already a member, sign in here.